PharmaEssentia (TWSE:6446) Full Year 2024 Results
Key Financial Results
- Revenue: NT$9.73b (up 91% from FY 2023).
- Net income: NT$2.97b (up from NT$623.8m loss in FY 2023).
- Profit margin: 31% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
- EPS: NT$8.96 (up from NT$1.93 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
PharmaEssentia Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 1.9%. Earnings per share (EPS) also surpassed analyst estimates by 5.7%.
In the last 12 months, the only revenue segment was Research and Development of New Drugs contributing NT$9.73b. The largest operating expense was Research & Development (R&D) costs, amounting to NT$2.59b (38% of total expenses). Over the last 12 months, the company's earnings were enhanced by non-operating gains of NT$1.23b. Explore how 6446's revenue and expenses shape its earnings.
Looking ahead, revenue is forecast to grow 38% p.a. on average during the next 2 years, compared to a 32% growth forecast for the Biotechs industry in Taiwan.
Performance of the Taiwanese Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for PharmaEssentia (1 doesn't sit too well with us!) that we have uncovered.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TWSE:6446
PharmaEssentia
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally.
Exceptional growth potential with flawless balance sheet.
